SynthesisFrontiers in medicine2025
The safety and efficacy of intravenous administration of tranexamic acid in off-pump coronary artery bypass grafting: a systematic review and meta-analysis.
Synthesis in Frontiers in medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Study objective: To assess the efficacy and safety of tranexamic acid (TXA) on off-pump coronary artery bypass (OPCAB) surgery. Design: Meta-analysis. Methods: Relevant trials were identified by computerized searches of PUBMED, Cochrane Library, EMBASE, OVID, China National Knowledge Infrastructure (CNKI), Wanfang Data and VIP Data till Aug 8th, 2025, were searched using search terms "Tranexamic acid," "coronary artery bypass grafting," "off-pump," "randomized controlled trial" database search was updated on Aug 10th, 2025. Primary outcomes included intraoperative and postoperative bleeding. Results: Nineteen randomized controlled trials were finally included in the current study. Intravenous TXA reduced intraoperative and postoperative bleeding volume (including 2, 4, 6, and 24-h postoperative bleeding). It also decreased the rate and volume of red blood cell (RBC) and fresh frozen plasma (FFP) transfusions, with no effect on reoperation rates due to postoperative bleeding. At 24 h postoperatively, TXA increased platelet counts, hemoglobin concentrations, and prothrombin time (PT), while decreasing activated partial thromboplastin time (APTT), fibrinogen levels, and D-dimer concentrations. Importantly, TXA did not elevate the risk of postoperative complications (e.g., mortality, myocardial infarction, cerebrovascular accidents, thrombotic events) and had no impact on levels of CK-MB, creatinine, interleukin-6, or lengths of intensive care unit (ICU) and hospital stays. Conclusion: Intravenous TXA is effective in reducing perioperative bleeding and transfusion requirements in OPCAB without increasing the risk of major postoperative complications, supporting its clinical utility in this setting. More well-designed and adequately powered RCTs are needed to confirm this further.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.